GSK’s RSVPreF3 OA vaccine (AREXVY) : AREXVY was approved by FDA on May 3, 2023, and is indicated for the prevention of LRTD disease caused by RSV in adults 60 and older, as a single dose

Friedland, Leonard

i

GSK’s RSVPreF3 OA vaccine (AREXVY) : AREXVY was approved by FDA on May 3, 2023, and is indicated for the prevention of LRTD disease caused by RSV in adults 60 and older, as a single dose

Public Domain

June 21, 2023
By Friedland, Leonard
Series: ACIP: Respiratory Syncytial Virus (RSV)

File Language:

English

Details

Personal Author:

Friedland, Leonard
Corporate Authors:

GSK Vaccines.
Description:

03-RSV-Adults-Friedland-508.pdf
Subjects:

Respiratory Syncytial Virus Infections/prevention & Control Respiratory Syncytial Virus Vaccines
Series:

ACIP: Respiratory Syncytial Virus (RSV)
Document Type:

Still Image
Name as Subject:

ACIP meeting: 2023 Jun 21 ; ACIP meeting: 2023 Jun 21
Genre:

Presentation ; Conference Publications
Pages in Document:

22 numbered slides
Volume:

20230201
Collection(s):

Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:

urn:sha-512:5887e17964b001025881cee682401dd25c2b0869afdcdfca0649177d0c54054b59237f83e1865b064378612f03230a6446f5b7ce403aab23cf4877085187014c
Download URL:

https://stacks.cdc.gov/view/cdc/129993/cdc_129993_DS1.pdf
File Type:

[PDF - 1.21 MB ]

File Language:

English

ON THIS PAGE

Details Related Documents

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.